Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in acute myeloid leukemia
NCT06572982Active, not recruiting
- Sponsor
- Hikma Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML), sponsored by Hikma Pharmaceuticals. Primary endpoint: Adverse Events at 12 months. Started Apr 2025; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06572982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572982.